Navigation Links
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
Date:2/27/2009

transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K/A for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on April 29, 2008. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

(Tables Attached)

The following tables present Endo's unaudited net sales for the three months and year ended December 31, 2008 and December 31, 2007:

                     Endo Pharmaceuticals Holdings Inc.
                           Net Sales (unaudited)
                              (in thousands)

                                             
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... When families in Coral Gables get hit ... The new answer is Lice Troopers . Located at ... newest treatment center will be the new go-to resource for ... the use of harmful chemicals or pesticides. , ... 2015. Like the company’s first clinic (located at 1005 Kane ...
(Date:12/21/2014)... New York, NY (PRWEB) December 21, 2014 ... is nearing 1,400 in a consolidated litigation underway in ... court documents, a total of 1,375 claims involving the ... County Superior Court. These lawsuits were filed by women ... claim to have led to uterine perforations and other ...
(Date:12/21/2014)... SCI explores disability in sports this ... for disabled athletes with Aaron Scheidies , legally ... called juvenile macular degeneration, where he loses his central ... athletic ambitions to his vision and how he has ... the way for other blind and visually impaired athletes. ...
(Date:12/21/2014)... 21, 2014 Concept Plus, LLC. a ... headquartered in Fairfax, VA., today announced it has been ... 50 list, which ranks the fastest growing government contracting small ... to 2013. , This is the first year that Concept ... # 20 with a 95.92% compound annual growth rate. “For ...
(Date:12/20/2014)... December 20, 2014 An improving macroeconomic ... have benefited the Massage Services industry over ... of industry products, the anticipated 1.0% annualized increase in ... provided consumers with the means to afford additional massages. ... a massage in a given year has declined from ...
Breaking Medicine News(10 mins):Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ASV) ... US $62 million for the third,quarter of 2007 ... third quarter,of 2006. As previously announced, Aspreva ... 31, 2007. The Company will hold a conference,call ...
... 16 Genzyme Corporation,(Nasdaq: GENZ ) today ... Committee meeting, during which the committee voted 8 ... FDA extend the indications,for phosphate binders to use ... (sevelamer hydrochloride), the most,prescribed phosphate binder in the ...
... Oct. 16 The Cambridge Group, a leading,strategy ... Shea,principals of the firm. Mr. Miller brings ... experience to The Cambridge Group. In his career, ... in senior,executive and consulting positions. In his most ...
... Oct. 16 Mach One Corporation (Pink,Sheets: MNCN) is ... registration,with the Securities and Exchange Commission. The company had ... under the,1934 Act, and today made it official. The ... following the effectiveness of the SB-2. "This is a,monumental ...
... 16 The Center for the Internet & Digital,Medicine ... Eleanor,Herriman, MD, MBA, will chair a panel on Business ... at the 3rd Annual World,Healthcare Innovation and Technology Congress ... from 2 to 3 pm. CIDM develops and ...
... With both the Senate and,House expected to vote this ... Health Insurance Program (SCHIP) legislation, U.S.,Senator Sherrod Brown (D-OH) ... came together on a news conference call to urge ... The SCHIP legislation would provide $35 billion in ...
Cached Medicine News:Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 2Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 3Health News:Aspreva Announces Preliminary Revenues for Third Quarter 2007 4Health News:Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease 2Health News:Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease 3Health News:The Cambridge Group Names Two New Principals 2Health News:Mach One Corporation Files its Form SB-2 with the SEC 2Health News:CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0 2Health News:Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 2
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Consulting, a business unit of PAREXEL International (Nasdaq: ... serving the biopharmaceutical and medical device industries, today released ... provide key insights into emerging areas of biosimilar development. ... Consultant and Cecil Nick, B.Sc. (Hons), Vice President, Biotechnology, ...
... of Primary Astrocytes With Anti-GLAST MicroBeads -- BERGISCH GLADBACH, Germany, September 22, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 2PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 3PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 4PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 2Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 3Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 4Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 6
... hoods are designed to rest on the ... stream of air across the top of ... sizes and types of hoods such as ... on special order in materials such as ...
... is an economical unit designed for small ... of fume hoods are needed. Excellent for ... Features include a one-piece shell molded of ... for easy cleaning. A clear acrylic panel ...
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
Single side double clamp knife holder for the Vibratome 8000...
Medicine Products: